# Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer

> **NCT04067986** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Zhongshan Hospital Xiamen University** · enrollment: 62 (estimated)

## Conditions studied

- Colorectal Cancer Recurrent

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT04067986
- **Lead sponsor:** Zhongshan Hospital Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-20
- **Primary completion:** 2020-09-23
- **Final completion:** 2021-10-31
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2020-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04067986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04067986, "Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04067986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*